Vivoryon Therapeutics N.V. – LSE:0R3M.L
Vivoryon Therapeutics N.V. stock price today
Vivoryon Therapeutics N.V. stock price monthly change
Vivoryon Therapeutics N.V. stock price quarterly change
Vivoryon Therapeutics N.V. stock price yearly change
Vivoryon Therapeutics N.V. key metrics
Market Cap | 51.29M |
Enterprise value | N/A |
P/E | N/A |
EV/Sales | N/A |
EV/EBITDA | N/A |
Price/Sales | N/A |
Price/Book | N/A |
PEG ratio | N/A |
EPS | -2.37 |
Revenue | N/A |
EBITDA | -58.18M |
Income | -56.49M |
Revenue Q/Q | N/A |
Revenue Y/Y | N/A |
Profit margin | 0% |
Oper. margin | 0% |
Gross margin | 0% |
EBIT margin | 0% |
EBITDA margin | N/A |
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeVivoryon Therapeutics N.V. stock price history
Vivoryon Therapeutics N.V. stock forecast
Vivoryon Therapeutics N.V. financial statements
| Jun 2022 | 0 | -12.58M | |
|---|---|---|---|
| Dec 2022 | 0 | -15.57M | |
| Jun 2023 | 0 | -10.71M | |
| Dec 2023 | -3.62M | -17.62M | 486.91% |
| 2025 | -2.03M | -14.76M | 725.19% |
|---|---|---|---|
| 2026 | -1.52M | -14.89M | 975.18% |
| 2027 | 339.7M | -14.13M | -4.16% |
| 2028 | -859.04K | -15.14M | 1763.04% |
Analysts Price target
Financials & Ratios estimates
| Sep 2022 | 31378 | 4.87K | 15.53% |
|---|---|---|---|
| Dec 2022 | 31378 | 4.87K | 15.53% |
| Jun 2023 | 45355000 | 3.82M | 8.42% |
| Dec 2023 | 30829000 | 4.54M | 14.75% |
| Jun 2022 | -10.23M | -2K | 19.58M |
|---|---|---|---|
| Dec 2022 | -11.55M | -11K | 13.8M |
| Jun 2023 | -20.28M | -9K | 23.4M |
| Dec 2023 | -1.25M | -10.50M | 757K |
Vivoryon Therapeutics N.V. alternative data
| Aug 2023 | 15 |
|---|---|
| Sep 2023 | 15 |
| Oct 2023 | 15 |
| Nov 2023 | 15 |
| Dec 2023 | 15 |
| Jan 2024 | 15 |
| Feb 2024 | 15 |
| Mar 2024 | 15 |
| Apr 2024 | 15 |
| May 2024 | 15 |
| Jun 2024 | 15 |
| Jul 2024 | 15 |
Vivoryon Therapeutics N.V. other data
| Insider | Compensation |
|---|---|
Dr. Ulrich Dauer (1965) Chairman of the Management Board & Chief Executive Officer | $530,100 |
Dr. Michael Schaeffer Chief Bus. Officer & Member of the Management Board | $346,810 |
Manuela Bader Director of Investor Relations & Communications | |
Mr. Frank T. Weber M.D. Chief Medical Officer | |
Dr. Konrad Glund Co-Founder & Advisor | |
Dr. Hendrik Liebers Advisor |
-
What's the price of Vivoryon Therapeutics N.V. stock today?
One share of Vivoryon Therapeutics N.V. stock can currently be purchased for approximately $18.69.
-
When is Vivoryon Therapeutics N.V.'s next earnings date?
Unfortunately, Vivoryon Therapeutics N.V.'s (0R3M.L) next earnings date is currently unknown.
-
Does Vivoryon Therapeutics N.V. pay dividends?
No, Vivoryon Therapeutics N.V. does not pay dividends.
-
How much money does Vivoryon Therapeutics N.V. make?
Vivoryon Therapeutics N.V. has a market capitalization of 51.29M.
-
What is Vivoryon Therapeutics N.V.'s stock symbol?
Vivoryon Therapeutics N.V. is traded on the LSE under the ticker symbol "0R3M.L".
-
What is Vivoryon Therapeutics N.V.'s primary industry?
Company operates in the Healthcare sector and Medical - Pharmaceuticals industry.
-
How do i buy shares of Vivoryon Therapeutics N.V.?
Shares of Vivoryon Therapeutics N.V. can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Vivoryon Therapeutics N.V.'s key executives?
Vivoryon Therapeutics N.V.'s management team includes the following people:
- Dr. Ulrich Dauer Chairman of the Management Board & Chief Executive Officer(age: 60, pay: $530,100)
- Dr. Michael Schaeffer Chief Bus. Officer & Member of the Management Board()
- Manuela Bader Director of Investor Relations & Communications
- Mr. Frank T. Weber M.D. Chief Medical Officer
- Dr. Konrad Glund Co-Founder & Advisor
- Dr. Hendrik Liebers Advisor
-
Is Vivoryon Therapeutics N.V. founder-led company?
Yes, Vivoryon Therapeutics N.V. is a company led by its founder Dr. Konrad Glund.
-
How many employees does Vivoryon Therapeutics N.V. have?
As Jul 2024, Vivoryon Therapeutics N.V. employs 15 workers.
-
When Vivoryon Therapeutics N.V. went public?
Vivoryon Therapeutics N.V. is publicly traded company for more then 10 years since IPO on 23 Apr 2015.
-
What is Vivoryon Therapeutics N.V.'s official website?
The official website for Vivoryon Therapeutics N.V. is vivoryon.com.
-
How can i contact Vivoryon Therapeutics N.V.?
Vivoryon Therapeutics N.V. can be reached via phone at +49 345 5559900.
Vivoryon Therapeutics N.V. company profile:
Vivoryon Therapeutics N.V.
vivoryon.comLSE
15
Medical - Pharmaceuticals
Healthcare
Vivoryon Therapeutics N.V., a clinical stage biopharmaceutical company, engages in the research and development of therapeutic products for the treatment of Alzheimer's disease. Its pipeline products target toxic pyroglutamate-Abeta (pGlu-Abeta), which inhibits the production of pGlu-Abeta. The company's lead product candidate is PQ912, a small molecule QC inhibitor that has completed Phase IIb clinical trials for use in the treatment of Alzheimer's disease; and for the treatment of cancer. Its preclinical development product is PQ1565, a small molecule glutaminyl-peptide cyclotransferase-like inhibitor for the treatment of cancer. In addition, the company is developing a monoclonal antibody targeting pGlu-Abeta to enhance its clearance. Vivoryon Therapeutics N.V. has a research collaboration agreement with University Medical Center Schleswig-Holstein to discover and develop therapeutics in cancer immunotherapy; collaboration agreement with Nordic Bioscience for the clinical development of PQ912 for Alzheimer's disease; and research collaboration with the Fraunhofer Institute for cell therapy and immunology, as well as a strategic regional licensing partnership with Simcere Pharmaceutical Group Ltd. to develop and commercialize medicines targeting the neurotoxic amyloid species N3pE (pGlu-Abeta) to treat Alzheimer's disease. Vivoryon Therapeutics N.V. was founded in 1997 and is headquartered in Halle, Germany.
Halle, 06120
:
ISIN: NL00150002Q7
:
